More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$54.38B
EPS
14.84
P/E ratio
36.4
Price to sales
8.96
Dividend yield
--
Beta
1.545653
Previous close
$700.65
Today's open
$701.14
Day's range
$687.72 - $706.76
52 week range
$500.61 - $769.98
show more
CEO
Jonathan J. Mazelsky
Employees
11000
Headquarters
Westbrook, ME
Exchange
Nasdaq Global Select
Shares outstanding
78786265
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
3 Stocks Rallying After Strong Q3 Earnings and Raised Guidance
The Q3 earnings season has delivered several big winners, with Hasbro (HAS), IDEXX Laboratories (IDXX), and TG Therapeutics (TGTX) all posting strong results that have helped drive relative strength over the last month, with each raising also guidance in one way or another.
Zacks Investment Research • Nov 17, 2026

3 Reasons Growth Investors Will Love Idexx (IDXX)
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks Investment Research • Nov 6, 2026

IDEXX Laboratories: Q3 Results Confirm They Are Best-In-Class
IDEXX Laboratories delivered strong Q3 results, beating expectations with 9.86% organic revenue growth and raising full-year revenue and EPS guidance. I maintain my buy rating on IDXX, citing its best-in-class diagnostics, high recurring revenue, and robust innovation pipeline supporting premium valuation. CoVet acquisition adds high-margin, AI-driven workflow software, enhancing stickiness and cross-selling, with a calculated purchase price near $223 million and double-digit growth potential.
Seeking Alpha • Nov 4, 2026

IDEXX Laboratories: Great Company, But Too Expensive (Rating Downgrade)
IDEXX Laboratories continues to demonstrate robust growth, with Q3/26 results prompting an upward revision of FY26 revenue guidance to 10.1%-10.8%. VetLab consumables and CAG department revenues grew 16.1% and 11.3% respectively in the first nine months, underscoring core business strength. IDXX maintains pricing power, consistently passing on price increases and offsetting inflation, as evidenced by improved gross and operating margins.
Seeking Alpha • Nov 4, 2026

Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors
From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Zacks Investment Research • Nov 3, 2026

IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund
Retirement savers who never chose IDEXX Laboratories (NASDAQ:IDXX | IDXX Price Prediction) got a lift from it anyway on Monday. The veterinary diagnostics company was up 20.2% in the regular session as of 1:54 PM ET, trading at $662.
24/7 Wall Street • Nov 2, 2026

IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction
IDEXX grew third-quarter revenue 10% to about $1.21 billion, led by an 11% gain in recurring diagnostics sales to vets. The higher 2026 profit forecast doesn't come from testing demand.
The Motley Fool • Nov 2, 2026

Idexx Labs Barks Up A Third-Quarter Beat; Can It Fetch This Next Bullish Move?
Idexx Laboratories outperformed a shaky macro on Monday, beating third-quarter forecasts. Idexx stock surged.
Investors Business Daily • Nov 2, 2026

IDEXX raises forecast, betting diagnostics can offset weak vet visits
IDEXX Laboratories beat quarterly estimates and raised its annual profit and revenue forecast on Monday, betting that rising diagnostic use per visit and new product launches will sustain growth through softer veterinary clinic traffic.
Reuters • Nov 2, 2026

IDEXX Laboratories Q3 Earnings Call Highlights
IDEXX Laboratories NASDAQ: IDXX reported third-quarter 2026 results marked by organic revenue growth, higher diagnostic utilization and expanded placement of its premium instruments, while raising its full-year revenue and earnings outlook.
MarketBeat • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell IDEXX Laboratories Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.